# Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

> **NCT02197234** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 52 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **PROCEDURE:** Pharmacokinetic sampling - AZD9291
- **DRUG:** Simvastatin
- **DRUG:** AZD9291 tablet dosing
- **PROCEDURE:** Pharmacokinetic sampling - simvastatin
- **PROCEDURE:** Pharmacokinetic sampling - AZ5140 and AZ7550

## Key facts

- **NCT ID:** NCT02197234
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-22
- **Primary completion:** 2015-04-30
- **Final completion:** 2024-06-03
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02197234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02197234, "Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02197234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*